Clinical trials: Physical Activities
Psychomotor Agitation, Schizophrenia
A Study of Staccato Loxapine (ADASUVE®) for Inhalation
Phase 3 safety and efficacy study of Staccato Loxapine in the treatment of acute agitation in schizophrenic or bipolar disorder patients.
- Conditions
- Psychomotor Agitation, Schizophrenia, Bipolar Disorder
- Trial name
- NCT04148963
- Testing
- Inhaled loxapine
- Volunteers
- 150 people
- Sponsor
- Lee's Pharmaceutical Limited
Treatment, Osteoarthritis
Evaluate Safety & Efficacy of Condroflex in Subjects With OA
Primary Objective: To compare, after 12 weeks of double-blind treatment, the evolution of the improvement of pain (at rest and during / after exercise) in the questionnaire WOMAC (Western Ontario and McMaster Universities…
- Conditions
- Treatment, Osteoarthritis, Elderly
- Trial name
- ZD20108 (NCT00838487)
- Testing
- condroflex and exercise, sugar pill and exercise
- Where
- Brazil
- Volunteers
- 240 people
- Sponsor
- Zodiac Produtos Farmaceuticos S.A.
COPD
Effect of QVA149 on Exercise Tolerance in Patients With Chronic Obstructive Pulmonary Disease (COPD)
This study assessed the effect of once-daily indacaterol and glycopyrronium bromide (QVA149) on exercise endurance in patients with moderate to severe Chronic Obstructive Pulmonary Disease (COPD).
- Trial name
- BRIGHT (NCT01294787)
- Testing
- indacaterol and glycopyrronium bromide (QVA149), tiotropium
- Where
- 13 sites in Germany, Spain
- Volunteers
- 85 people
- Sponsor
- Novartis Pharmaceuticals
Mood, Depression Disorders
Technology Exposure and Child Health: Wellness Impact and Social Effects: An Observational Product Registry Study
The goal of this study is to understand how children's mobile device usage (smartphones or tablets), including social media use and online games, are related to their mental wellness and mental health, as well as some aspects of…
- Conditions
- Mood, Depression Disorders, Anxiety Disorders, Sleep
- Trial name
- TECHWISE (NCT06664944)
- Where
- United States
- Volunteers
- 912 people, healthy volunteers welcome
- Sponsor
- Aura
Pulmonary Disease, Chronic Obstructive
Effect of Treatment With BIIL 284 BS on Exercise Endurance in Patients With Chronic Obstructive Pulmonary Disease
Study to investigate the effect of 12-week treatment with three doses (5, 25 and 75 mg) BIIL 284 BS on exercise endurance, lung function, quality of life, spontaneous sputum and safety in patients with chronic obstructive…
- Trial name
- NCT02249247
- Testing
- Low dose of BIIL 284 BS tablets, Medium dose of BIIL 284 BS tablets, High dose of BIIL 284 BS tablets
- Volunteers
- 577 people
- Sponsor
- Boehringer Ingelheim
Stress Urinary Incontinence, Mixed Urinary Incontinence
Comparing Use of a Digital Health System of Pelvic Floor Exercise Program to Kegel Exercises in Stress Urinary Incontinence
A randomized controlled trial for patients with stress urinary incontinence or stress-dominant mixed incontinence. Subjects will be randomized to 8-weeks of home kegel exercises or 8 weeks of pelvic floor muscle exercises using…
- Trial name
- NCT03632447
- Testing
- Leva, PFDx
- Where
- 7 sites in United States
- Volunteers
- 77 people
- Sponsor
- Renovia, Inc.
Stable Angina
Treadmill Cardiovascular Safety Study of Erenumab (AMG 334)
A phase 2a, multicenter, randomized, double-blind, placebo-controlled study in adults with stable angina to evaluate the effect of erenumab (AMG 334) compared to placebo on exercise time during an exercise treadmill test.
- Trial name
- NCT02575833
- Testing
- Erenumab
- Where
- 33 sites in United States, Bulgaria and 8 more
- Volunteers
- 89 people
- Sponsor
- Amgen
Agitation, Dementia
Dexmedetomidine in the Treatment of Agitation Associated With Dementia (TRANQUILITY II)
A study to determine the safety and efficacy of BXCL501 dosing for episodes of agitation associated with dementia when they occur (given as needed [PRN]), for a maximum of 28 doses within a 12-week treatment period.
- Trial name
- NCT05271552
- Testing
- BXCL501
- Where
- 11 sites in United States
- Volunteers
- 151 people
- Sponsor
- BioXcel Therapeutics Inc
Sports Physical Therapy, Dietary Habits
Investigating the Effects of Diet and Physical Activity on Esport Performance
A randomized, counterbalanced intervention study in esport players.
- Conditions
- Sports Physical Therapy, Dietary Habits, Diet, Healthy
- Trial name
- NCT05881018
- Testing
- Low glycaemic index, High glycaemic index, Physical activity
- Where
- Germany
- Volunteers
- 54 people, healthy volunteers welcome
- Sponsor
- Beneo-Institute
Alzheimer's Disease
24 Months Safety and Efficacy Study of AADvac1 in Patients With Mild Alzheimer's Disease
This study evaluates the safety and efficacy of AADvac1 in the treatment of patients with mild Alzheimer's disease. 60% of participants will receive AADvac1 and 40% of participants will receive placebo.
- Trial name
- ADAMANT (NCT02579252)
- Testing
- AADvac1
- Where
- 42 sites in Austria, Czechia and 6 more
- Volunteers
- 208 people
- Sponsor
- Axon Neuroscience SE
Exercise-induced Bronchospasm
Comparison of Two Bronchodilator Inhalers in Adolescents and Adults With Exercise-Induced Asthma
This study was designed to examine the effectiveness of two bronchodilator inhalers in patients who have exercise-induced asthma.
- Trial name
- NCT00085774
- Testing
- albuterol aerosol by HFA MDI, albuterol aerosol by HFA BOI
- Where
- 3 sites in United States
- Volunteers
- 24 people
- Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
Type 2 Diabetes Mellitus
MK-0431/ONO-5435 Phase III Clinical Trial - Insulin Add-on Study for Patients With Type 2 Diabetes Mellitus
This Phase III clinical trial will examine the efficacy, safety, and tolerability of the addition of MK-0431/ONO-5435 to Japanese patients with Type 2 Diabetes Mellitus who have inadequate glycemic control on diet/exercise…
- Trial name
- NCT00854035
- Testing
- MK-0431/ONO-5435
- Where
- 7 sites in Japan
- Volunteers
- 266 people
- Sponsor
- Ono Pharmaceutical Co., Ltd.
Amyotrophic Lateral Sclerosis
Study to Investigate the Safety of the Transplantation (by Injection) of Human Glial Restricted Progenitor Cells (hGRPs; Q-Cells®) Into Subjects With Amyotrophic Lateral Sclerosis (ALS)
This study is a non-randomized, open-label, partially blinded, sequential cohort, dose-escalation study designed to obtain preliminary data on the safety, tolerability, and early efficacy of Q-Cells® transplantation in subjects…
- Trial name
- NCT02478450
- Testing
- Q-Cells
- Volunteers
- 30 people
- Sponsor
- Q Therapeutics, Inc.
Type 2 Diabetes
A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Placebo in People With Type 2 Diabetes Treated With Diet and Exercise
This study will look at how much CagriSema helps participants with type 2 diabetes lower their blood sugar and body weight. CagriSema is a new investigational medicine. Doctors may not yet prescribe CagriSema.
- Trial name
- REIMAGINE 1 (NCT06323174)
- Testing
- Cagrilintide, Semaglutide
- Where
- 50 sites in United States, China and 5 more
- Volunteers
- 189 people
- Sponsor
- Novo Nordisk A/S
Diabetes Mellitus, Type 2
Empagliflozin (BI 10773) Dose Finder Study in Japanese Patients With Type 2 Diabetes Mellitus
This study is conducted to determine the most appropriate therapeutic doses of BI 10773 in Japanese patients with T2DM at first treatment period.
- Trial name
- NCT01193218
- Testing
- BI 10773
- Where
- 32 sites in Japan
- Volunteers
- 547 people
- Sponsor
- Boehringer Ingelheim
Heart Failure, Congestive
A Multi-center, Placebo-controlled Study to Evaluate the Safety of GSK716155 and Its Effects on Myocardial Metabolism, Myocardial Function, and Exercise Capacity in Patients With NYHA Class II/III Congestive Heart Failure
This exploratory proof of concept study will be conducted in patients with stable New York Heart Association (NYHA) Class II-III heart failure.
- Trial name
- NCT01357850
- Testing
- GSK716155
- Where
- 15 sites in United States, United Kingdom
- Volunteers
- 82 people
- Sponsor
- GlaxoSmithKline
Type 2 Diabetes Mellitus
Efficacy and Safety of HD-6277 in Adult Patients with Inadequate Control of Type 2 Diabetes Mellitus by Diet and Exercise
A Multi-center, Double-blind, Randomized, Placebo-controlled, Parallel-group, Phase 2 Study to Assess the Efficacy and Safety of HD-6277 in Adult Patients With Inadequate Control of Type 2 Diabetes Mellitus by Diet and Exercise
- Trial name
- NCT05666128
- Testing
- HD-6277
- Where
- South Korea
- Volunteers
- 112 people
- Sponsor
- Hyundai Pharm
Obesity
Cities for Better Health Childhood Obesity Prevention Initiative
This research project is part of the 'Cities for Better Health Childhood Obesity Prevention Initiative' (CBH COPI). The objective of the CBH COPI initiative is to develop, implement, and evaluate the effectiveness of a package of…
- Trial name
- CBH COPI (NCT06855563)
- Testing
- Community-based intervention packages
- Where
- 6 sites in Australia, Brazil and 4 more
- Volunteers
- 36,000 people
- Sponsor
- Novo Nordisk A/S
Cardiomyopathy, Hypertrophic, Cardiomyopathy, Hypertrophic, Familial
Open-Label Study of Perhexiline in Patients With Hypertrophic Cardiomyopathy and Moderate to Severe Heart Failure
The purpose of this study is to evaluate the effect of perhexiline on exercise performance (efficacy) and safety in patients with hypertrophic cardiomyopathy and moderate-to-severe heart failure following dosing for 16 weeks.
- Trial name
- NCT02862600
- Testing
- Perhexiline, Use of bioanalytical assay to monitor plasma levels of perhexiline
- Where
- 11 sites in United States
- Volunteers
- 35 people
- Sponsor
- Heart Metabolics Limited
Alzheimer Disease, Agitation,Psychomotor
Clinical Trial on Agitation in Alzheimer's Dementia
The purpose of this study is to assess the efficacy of the oral medication IGC-AD1, a THC-based (Delta-9-Tetrahydrocannabinol) formulation administered twice a day on Agitation in patients with mild to severe dementia from…
- Conditions
- Alzheimer Disease, Agitation,Psychomotor, Care Giving Burden, NPS
- Trial name
- CALMA (NCT05543681)
- Testing
- IGC-AD1-Active
- Where
- 28 sites in United States, Canada and 1 more
- Volunteers
- 164 people
- Sponsor
- IGC Pharma, LLC